Setting new standards in information exchange for the pharmaceutical and biotech industry
Announcing Immuno-Oncology KOL Panel at the JPM Health Week in San Francisco
January 9, 2017
We are pleased to announce that the IO360 team at the Conference Forum together with BioPharm Insight are co-presenting a panel discussion on Immuno-Oncology: Filtering the Hype for the Next Wave of Targets along side the JP Morgan HealthCare conference. The panel discussion will take place January 9, 2017 at the Chandran Art Gallery in San Francisco. Following the discussion, there will be a networking reception.
Panel Discussion: 5:30 – 6:30 pm
Immuno-Oncology: Filtering the Hype for the Next Wave of Targets
Key opinion leaders (KOLs) and industry experts address timely issues in the immuno-oncology field including, but not limited to next-generation I/O therapeutics, check point inhibitors, combinations, pricing and reimbursement expectations, and more.
Axel Hoos, MD, PhD
SVP Oncology R&D, GSK and Co-Chair, IO360
Ira Mellman, PhD
VP, Cancer Immunology, Genentech
Partner, Tapestry Networks
Omid Hamid, MD
Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic
Ramy Ibrahim, MD
VP and Head of R&D, Parker Institute for Cancer Immunotherapy
Editor-in-Chief, BioPharm Insight
Reception 6:30 – 8:30 pm
This is a complimentary limited seating event. RSVP is required. To register, please click here.
Chandran Art Gallery
459 Geary Street
San Francisco, CA 94102
* Please note, the panel portion of the event is expected to sell out so register quickly. More attendance will be open for the networking portion of the event.